IRX4204 is a synthetic orally bioavailable small molecule, with potent and highly selective RXR agonist profile. IRX4204 is a lipophilic molecule with good blood brain barrier permeability. It has successfully completed phase I/IIA clinical trials in various solid tumors, prostate cancer, lung cancer, and Parkinson’s disease with over 100 patients treated.

Treatment with retinoid X receptor agonist IRX4204 ameliorates experimental autoimmune encephalomyelitis

Selective brain penetrable Nurr1 transactivator for treating Parkinson’s disease